Health Care M&A Weekly Deals, The Week Ending July 28, 2017
Acquisition data from Q2:17 shows pharmaceutical deal volume continues its steep downward decline. (See chart) (more…)
Fresenius, a global leader in dialysis, brings dialysis into the home with a $2 billion deal. (more…)
A few CROs, like PRA Health Sciences, are turning to eHealth acquisitions to strengthen their data technology capabilities. (more…)
KKR & Co., through its portfolio company, is the second private equity firm to pay more than $2 billion for a medical transportation company in 2017. (more…)
This monthly feature focuses on various tranches and rounds of funding for healthcare ventures, startups and funds. Links indicate target companies and lead investors.
The Managed Care sector went two steps forward, then one step back in July. Two deals were announced in the span of two days, and as the month neared a close, another deal was terminated, leaving this year’s total at a sluggish 10 deals.
Merger and acquisition activity stayed virtually even in the second quarter, down 1% from the previous quarter, to 75 transactions. The quarter’s deal volume makes up 24% of the 315 deals announced within the past 12 months. Q2:17’s deal volume is 17% lower than the same period a year earlier.
A portfolio company of KKR (NYSE: KKR) just announced the 99th eHealth deal of 2017, and the second largest eHealth deal in our M&A database dating back to 1993.
The Home Health & Hospice sector has experienced a few headwinds in 2017. Besides the ongoing labor shortage, reimbursement levels would be severely impacted by the passage of the Senate Republicans’ Better Care Reconciliation Act, which curtails federal spending on Medicaid beginning in 2020.
Health Care M&A Weekly Deals, The Week Ending July 21, 2017
Deal activity in the Behavioral Health Care sector plummeted in Q2:17, down 50% compared with the previous quarter, and down 53% compared with the same quarter a year earlier. The quarter’s total of eight deals represents 21% of the 39 transactions announced in the past 12 months. In fact, those two quarters—Q1:17 and Q2:16—had the […]
Since February 2016, we’ve followed the testy merger between Abbott (NYSE: ABT) and Alere’s (NYSE: ALR) agreement to merge, followed by the respective lawsuits, and then the price renegotiation. Half way through 2017, the $5.3 billion deal is getting closer to completion, as Alere spins off some assets to comply with antitrust regulations.
Early in July, Sanofi (NYSE: SNY) announced an acquisition and a divestment, both affecting its vaccine business. In a recent annual filing, Sanofi labelled its vaccine unit as an area of priority to sustain its leadership role. To that end, the company has expanded its influenza vaccine portfolio and shed its small pox vaccine business, including […]